SCHEDULE: RA Capital Reduces Stake in Werewolf Therapeutics

RA Capital Management reports a reduction in its beneficial ownership of Werewolf Therapeutics common stock following recent open market sales.

Summary

• RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, filed an amendment to their Schedule 13D regarding Werewolf Therapeutics, Inc.
• The reporting persons now beneficially own 6,116,140 shares of common stock, representing 12.6% of the outstanding class.
• The filing details open market sales of shares occurring between May 8, 2026, and May 12, 2026.
• Total shares sold across these dates amounted to 565,167 shares at prices ranging from $0.62 to $0.76 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the active selling of shares by a major institutional investor, which may create downward pressure on the stock price.

Positives

• The reporting persons maintain a significant 12.6% ownership stake, indicating continued, albeit reduced, institutional interest.

Negatives

• The reporting persons have actively reduced their position through open market sales over several days in May 2026.
• The sales were executed at prices between $0.62 and $0.76, reflecting a low valuation relative to historical highs.

Risks

• Continued selling pressure from a major institutional shareholder may negatively impact the stock price.
• The reduction in stake by a prominent healthcare-focused investment firm could be perceived as a lack of confidence in near-term catalysts.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but indicates the reporting persons continue to monitor their investment.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotech firms often signals a shift in portfolio strategy or a reaction to clinical trial timelines, rather than necessarily reflecting the fundamental health of the issuer.

Comparison to Industry Standards

• The 12.6% ownership level remains substantial for an institutional investor in the small-cap biotechnology sector.
• Open market sales by major holders are common in the biotech sector as funds rebalance portfolios or manage liquidity.

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders may experience increased volatility due to the institutional selling activity.

Next Steps

• Continued monitoring of further Form 4 or Schedule 13D filings to determine if the reporting persons intend to further reduce their position.

Key Dates

Recommendation

While the reduction in stake is a negative signal, the reporting group still maintains a significant 12.6% position, suggesting they are not exiting the investment entirely at this time.

Keywords

Werewolf Therapeutics, RA Capital, Schedule 13D, Biotech, Insider Selling, Institutional Ownership